Korea Pharma

한국파마 · 032300

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$74.2M (₩102.4B)

Overview

Korea Pharma makes prescription medicines, tablets, capsules, liquids, and ointments, covering a broad range of conditions including mental-health disorders, digestive and cardiovascular diseases, infections, diabetes, and respiratory ailments.

Hospitals, clinics, and pharmacies in Korea and overseas markets across Asia, Africa, and the Middle East use its products. Listed on KOSDAQ, Korea's small-cap and technology board, the company runs three distinct business lines: manufacturing and supplying its own branded generics and improved formulations, contract manufacturing (CMO) for other pharmaceutical companies, and direct export of its product range.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$63.5M
▲ +7.8% YoY
Operating profit · FY2025
−US$643K
Turned to loss
Net income · FY2025
−US$1.9M
Turned to loss

Revenue

  • FY2023US$60.3M
  • FY2024US$58.9M
  • FY2025US$63.5M

Operating profit

  • FY2023US$4.5M
  • FY2024US$4.4M
  • FY2025−US$643K

Net income

  • FY2023US$60.7K
  • FY2024US$2.7M
  • FY2025−US$1.9M

Key ratios (FY2025)

ROE
-3.8%
Debt/Eq
84.1%
Op. margin
-1.0%
Net margin
-3.0%
Rev. YoY
▲ +7.8%

Why it matters

The company previously assigned a patent for an oral pharmaceutical composition containing choline alfoscerate to 대웅바이오㈜, indicating an established domestic licensing-out track record.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.